With the recent approval of a competitor to its pulmonary arterial hypertension franchise, United Therapeutics had a lot of explaining to do to analysts at the J.P. Morgan Healthcare Conference in San Francisco this week.
The biotech explained to investors and analysts that it's ready to take on competition from Actelion's new oral PAH drug Uptravi (selexipag), which was approved Dec. 22 by FDA